Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191263 | 0.80 | ADORA3 (0.47) | ADORA3NPY5RTMEM97SIGMAR1KDR | |
| SCHEMBL1999899 | 0.77 | MEN1 (0.61) | POLA1NPY5RCYP1A2MEN1KMT2A | |
| SCHEMBL1490746 | 0.74 | KDM4E (0.42) | — | |
| SCHEMBL1423650 | 0.69 | ADORA3 (0.56) | ADORA3NPY5RTMEM97SIGMAR1DRD3 | |
| SCHEMBL5569266 | 0.69 | EGFR (0.77) | NPY5RKDRMETRAB9AEGFR | |
| SCHEMBL936822 | 0.68 | ADORA3 (0.57) | ADORA3NPY5RTMEM97SIGMAR1KDR | |
| SCHEMBL6091625 | 0.66 | NPY5R (0.57) | ADORA3POLA1NPY5RTMEM97SIGMAR1 | |
| SCHEMBL27397193 | 0.66 | NPY5R (0.57) | ADORA3NPY5RTMEM97SIGMAR1DRD3 | |
| SCHEMBL18418447 | 0.66 | MEN1 (0.57) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2002403 | 0.66 | MEN1 (0.57) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326978-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-03 | — | — | US | claimed |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2013-08-01 | — | — | US | claimed |
| US-8420664-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | claimed |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | THE GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2009-02-26 | — | — | US | claimed |
| EP-1983990-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007089507-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2007-08-09 | — | — | WO | claimed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2020-09-22 | — | — | US | disclosed |
| WO-2014024195-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2014-02-13 | — | — | WO | disclosed |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2013-08-01 | — | — | US | disclosed |
| US-8420664-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1983990-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | US GOV HEALTH & HUMAN SERV (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | THE GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1983990-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089507-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | ADORA3 5/4885POLA1 2023/4885NPY5R 1873/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885POLA1 2767/4885NPY5R 2068/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | ADORA3 1/4885POLA1 4758/4885NPY5R 619/4885 |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885POLA1 2986/4885NPY5R 1323/4885 |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885POLA1 2730/4885NPY5R 636/4885 |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA3 13/4885POLA1 1602/4885NPY5R 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.